Inovio has benefited from having a head start on many other coronavirus vaccine manufacturers. It was one of the first to begin human safety studies, an event that has helped to buoy its shares this year — even with Monday’s losses, they are worth nearly four times what they were at the start of 2020.
But since disclosing preliminary study results, without specifics, from an early-stage trial in June, the company’s progress has stalled. It hasn’t published detailed data from the Phase 1 trial or secured outside funding to start a further test.
